Updates are available Correction dated 2020-01-03
Click to view Correction: https://doi.org/10.1186/s40035-019-0182-8
-
Authors
Van Schependom, Jeroen
Guldolf, Kaat
D’hooghe, Marie Béatrice
Nagels, Guy
D’haeseleer, Miguel http://orcid.org/0000-0003-4378-0089
- License Information
-
More Information
Article History
Received: 16 August 2019
Accepted: 7 November 2019
First Online: 9 December 2019
Change Date: 3 January 2020
Change Type: Correction
Change Details: In the original publication of this article [1], the following statement should be added in the Acknowledgement section.
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: GN is a shareholder of icometrix which is a software provider for BV measurements, and currently on secondment from his employer (i.e. Universitair Ziekenhuis) to icometrix for 10% of his time in the role of ‘Medical Director Neurology’. MBD, GN and MD have received consultancy fees from the manufacturers of the disease-modifying treatments mentioned in the paper.
